Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12119
Full metadata record
DC FieldValueLanguage
dc.contributor.authorScheffer, Ingrid Een
dc.date.accessioned2015-05-16T01:46:05Z
dc.date.available2015-05-16T01:46:05Z
dc.date.issued2014-03-10en
dc.identifier.citationNeuropediatrics 2014; 45(2): 70-4en
dc.identifier.govdoc24615646en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12119en
dc.description.abstractEpilepsy genetics has undergone a revolution in the past 19 years since the discovery of the first gene for epilepsy. The story of our increasing knowledge and how it impacts on patient care is presented with reference to recent discoveries. Understanding the significance of a genetic variant is challenging both in terms of molecular pathogenicity and in how this finding fits into the rubric of causation. In some cases, it may only be a contributing susceptibility factor; whereas in others, it explains the patient's disease.A brief overview of the clinicomolecular approaches is discussed in the context of the discovery of epilepsy genes. These include family studies and, more recently, next generation sequencing using multigene panels and whole exome sequencing.Recent studies illustrating the way in which epilepsy genetics is changing clinical practice are described. A particular focus is DEPDC5, the first gene for nonlesional focal epilepsy likely to be relevant to sporadic patients with focal epilepsies and those from small families, in contrast to rare large families with autosomal dominant focal epilepsies. As DEPDC5 is a negative regulator of the mammalian target of rapamycin (mTOR) pathway, it is likely that some patients with DEPDC5 mutations may have malformations of cortical development akin to the two-hit hypothesis suggested in tuberous sclerosis. The greatest impact of epilepsy genetics at a clinical level is for patients with epileptic encephalopathies as many have de novo mutations-a rapidly expanding list of causative genes is being found.Epilepsy genetics is changing clinical practice enabling diagnosis in many patients, informing our understanding of comorbidities, prognosis, and genetic counseling. Importantly, a genetic finding may impact on treatment choices. At a biological level, new insights promise to lead to the development of novel therapies and bring together the seemingly disparate genetics of nonlesional epilepsies and epilepsies associated with cortical malformations.en
dc.language.isoenen
dc.subject.otherEpilepsy.diagnosis.geneticsen
dc.subject.otherGenetic Researchen
dc.subject.otherHumansen
dc.titleEpilepsy genetics revolutionizes clinical practice.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeuropediatricsen
dc.identifier.affiliationDepartment of Medicine, Florey Institute of Neurosciences and Mental Health, University of Melbourne, Austin Health, Melbourne, Australiaen
dc.identifier.doi10.1055/s-0034-1371508en
dc.description.pages70-4en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24615646en
dc.type.austinJournal Articleen
local.name.researcherScheffer, Ingrid E
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
24615646.pdf101.77 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

98
checked on Mar 28, 2024

Download(s)

90
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.